Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Cytomegalovirus Infections 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2obinutuzumab 1nelarabine 1letermovir 1ibrutinib 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic, B-Cell × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡